TherapeuticsMD (TXMD) Tops Q1 EPS by 1c

TherapeuticsMD (NASDAQ: TXMD) reported Q1 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $5.89 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Creatd files Form S-1 and reports Q1 2026 financial results
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold